<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biovaxys Technology Corp — News on 6ix</title>
<link>https://6ix.com/company/biovaxys-technology-corp</link>
<description>Latest news and press releases for Biovaxys Technology Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 29 Jan 2026 16:55:01 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biovaxys-technology-corp" rel="self" type="application/rss+xml" />
<item>
<title>BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-reports-positive-phase-2-165501753</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-reports-positive-phase-2-165501753</guid>
<pubDate>Thu, 29 Jan 2026 16:55:01 GMT</pubDate>
<description>Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer VANCOUVER, BC - January 29, 2026 (NEWMEDIAWIRE) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnol...</description>
</item>
<item>
<title>BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-reports-positive-clinical-study-130000795</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-reports-positive-clinical-study-130000795</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™...</description>
</item>
<item>
<title>BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-phase-1-clinical-130000553</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-phase-1-clinical-130000553</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is pleased to announce highly promising results from a two-arm phase 1 clinical study of the safety and...</description>
</item>
<item>
<title>BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-positive-phase-1-130000467</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-positive-phase-1-130000467</guid>
<pubDate>Wed, 17 Dec 2025 13:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is very pleased to announce positive results from a phase 1 clinical study of maveropepimut-S ("MVP-S") along..</description>
</item>
<item>
<title>BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-technology-corp-closes-listed-204100831</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-technology-corp-closes-listed-204100831</guid>
<pubDate>Wed, 19 Nov 2025 20:41:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, November 19, 2025--BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has closed its previously announced non-brokered private placement financing (the "Offering") of 11,311,676 units of the Company (the "Units") at an issue price of $0.17 per Unit for aggregate gross proceeds of $1,922,984.92.</description>
</item>
<item>
<title>BioVaxys Announces Extension of Life Offering Closing Date</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-extension-life-offering-202300408</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-extension-life-offering-202300408</guid>
<pubDate>Tue, 11 Nov 2025 20:23:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company”) announces an extension of its non-brokered private placement financing (the “Offering”) previously announced on October 7, 2025, in order to provide sufficient time for additional investors to participate in the Offering. The Offering is expected to close on or before November 20, 2025, or such other date as the Company may determine, subject to the satisf</description>
</item>
<item>
<title>BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-upsizing-life-offering-205400809</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-upsizing-life-offering-205400809</guid>
<pubDate>Thu, 30 Oct 2025 20:54:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces an increase to its non-brokered private placement financing (the "Offering") previously announced on October 7, 2025. The Offering will now consist of a minimum of 10,588,235 units of the Company ("Units") at an issue price of $0.17 per Unit to raise gross proceeds of $1,800,000 and up to a maximum of 11,764,705 Units for gross proceeds of up to $2,000,000.</description>
</item>
<item>
<title>BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-conversion-debentures-110000818</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-conversion-debentures-110000818</guid>
<pubDate>Tue, 28 Oct 2025 11:00:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding unsecured convertible debentures of the Company ("Debentures") pursuant to notices of conversion received from certain holders of the Debentures (the "Conversion").</description>
</item>
<item>
<title>BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-conversion-debentures-grant-233900107</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-conversion-debentures-grant-233900107</guid>
<pubDate>Mon, 20 Oct 2025 23:39:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding unsecured convertible debentures of the Company ("Debentures") pursuant to a notice of conversion received from a certain holder of the Debentures (the "Conversion").</description>
</item>
<item>
<title>BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-licensee-spayvac-wildlife-inc-120000571</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-licensee-spayvac-wildlife-inc-120000571</guid>
<pubDate>Tue, 14 Oct 2025 12:00:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to announce that results from a collaborative research project conducted in the Bavarian Forest National Park in Germany have recently been published in the European Journal of Wildlife Research.[1] A single-dose of its immunocontraceptive vaccine SpayVac™ vaccine ("SpayVac") significantly reduced fertility to 11% in vaccinated deer compared to a fertility rate of 86% in contro</description>
</item>
<item>
<title>BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-appoints-former-sanofi-vaccines-120000635</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-appoints-former-sanofi-vaccines-120000635</guid>
<pubDate>Wed, 08 Oct 2025 12:00:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that James Tartaglia, PhD, a former top R&D and commercial development executive with Sanofi Vaccines, has been appointed to the BioVaxys Board of Directors. Dr. Tartaglia fills a vacancy created by the resignation of Director Anthony Dutton, who has stepped down to focus on personal commitments. BioVaxys thanks Anthony for his outstanding service since his appointment in April 2022.</description>
</item>
<item>
<title>BIOVAXYS ANNOUNCES LIFE OFFERING</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-life-offering-213000244</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-life-offering-213000244</guid>
<pubDate>Tue, 07 Oct 2025 21:30:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it is undertaking a non-brokered private placement financing (the "Offering") consisting of a minimum of 7,058,824 units of the Company ("Units") at an issue price of $0.17 per Unit to raise gross proceeds of $1,200,000 and up to a maximum of 9,411,764 Units for gross proceeds of up to $1,600,000. Each Unit will consist of one common share of the Company (each, a "Share") and one common share purchase w</description>
</item>
<item>
<title>BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-horizon-technology-finance-corp-120000712</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-horizon-technology-finance-corp-120000712</guid>
<pubDate>Mon, 29 Sep 2025 12:00:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance Corporation ("Horizon") have executed a supplemental Amendment ("Amendment") to the Asset Purchase Agreement dated February 11th, 2024 ("APA") for acquiring the entire portfolio of assets and intellectual property based on the DPX™ immune educating platform technology developed by Canadian biotechnology company, IMV Inc.</description>
</item>
<item>
<title>BIOVAXYS ANNOUNCES CLOSING OF UNSECURED CONVERTIBLE DEBENTURE OFFERING</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-closing-unsecured-convertible-094400178</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-closing-unsecured-convertible-094400178</guid>
<pubDate>Tue, 16 Sep 2025 09:44:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement of unsecured convertible debentures (the "Debentures") for aggregate gross proceeds of $335,670 (the "Offering").</description>
</item>
<item>
<title>BIOVAXYS ANNOUNCES SHARE CONSOLIDATION</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-share-consolidation-210000188</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-share-consolidation-210000188</guid>
<pubDate>Fri, 05 Sep 2025 21:00:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces, further to its news release dated August 27, 2025, the consolidation of its common shares ("Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "Consolidation").</description>
</item>
<item>
<title>BIOVAXYS ANNOUNCES UNSECURED CONVERTIBLE DEBENTURE OFFERING AND CANCELLATION OF BROKERED LIFE OFFERING</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-unsecured-convertible-debenture-224000674</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-unsecured-convertible-debenture-224000674</guid>
<pubDate>Wed, 27 Aug 2025 22:40:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement of unsecured convertible debentures (the "Debentures") for aggregate gross proceeds of up to $500,000 (the "Offering").</description>
</item>
<item>
<title>BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-extension-offering-closing-221700216</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-extension-offering-closing-221700216</guid>
<pubDate>Tue, 15 Jul 2025 22:17:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces an extension of its previously announced brokered private placement LIFE financing (the "Offering") consisting of a minimum of 5,714,285 units of the Company (each, a "Unit") at a post-consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000.</description>
</item>
<item>
<title>BIOVAXYS ENGAGES ENCLAVE CAPITAL LLC TO ACT AS AN AGENT IN BROKERED PRIVATE PLACEMENT OFFERING</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-engages-enclave-capital-llc-203000541</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-engages-enclave-capital-llc-203000541</guid>
<pubDate>Mon, 07 Jul 2025 20:30:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces it has engaged Enclave Capital LLC ("Enclave") to act as an agent, in collaboration with D12 Capital Markets Inc. and its affiliate, Foundation Markets Inc., in connection with the Company's previously announced brokered private placement LIFE financing (the "Offering").</description>
</item>
<item>
<title>BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-amended-life-offering-062100430</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-announces-amended-life-offering-062100430</guid>
<pubDate>Fri, 20 Jun 2025 06:21:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has amended the terms of its brokered private placement LIFE financing (the "Offering") previously announced on May 30, 2025, and filed an amended offering document (the "Amended Offering Document"). The Amended Offering Document updates the exercise price of the common share purchase warrant that forms part of the units ("Units") being offered by the Company from a post-consolidation exercise price</description>
</item>
<item>
<title>BioVaxys Issues Corporate Update</title>
<link>https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-issues-corporate-225400665</link>
<guid isPermaLink="true">https://6ix.com/company/biovaxys-technology-corp/news/biovaxys-issues-corporate-225400665</guid>
<pubDate>Tue, 03 Jun 2025 22:54:00 GMT</pubDate>
<description>BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating initiatives including the integration and disposition of assets acquired in February 2024 from the former IMV, Inc., the non-exclusive out-licensing of DPX to human and animal health companies, restarting clinical studies---notably DPX-surMAGE in advanced bladder cancer, expansion of the BioVaxys pipeline a through new formulations based on the DPX™ immune educating</description>
</item>
</channel>
</rss>